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Abstract
Diamond–Blackfan anemia (DBA) is a rare genetic hypoplasia of erythroid progenitors charac-
terized by mild to severe anemia and associated with congenital malformations. Clinical mani-
festations in DBA patients are quite variable and genetic testing has become a critical factor in
establishing a diagnosis of DBA. The majority of DBA cases are due to heterozygous loss-of-
function mutations in ribosomal protein (RP) genes. Causative mutations are fairly straightfor-
ward to identify in the case of large deletions and frameshift and nonsense mutations found
early in a protein coding sequence, but diagnosis becomes more challenging in the case of mis-
sense mutations and small in-frame indels. Our group recently characterized the phenotype of
lymphoblastoid cell lines established from DBA patients with pathogenic lesions in RPS19 and
observed that defective pre-rRNA processing, a hallmark of the disease, was rescued by lentivi-
ral vectors expressing wild-type RPS19. Here, we use this complementation assay to determine
whether RPS19 variants of unknown significance are capable of rescuing pre-rRNA process-
ing defects in these lymphoblastoid cells as a means of assessing the effects of these sequence
changes on the function of the RPS19 protein. This approach will be useful in differentiating
pathogenicmutations from benign polymorphisms in identifying causative genes in DBA patients.
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1 INTRODUCTION
Diamond–Blackfan anemia (DBA) is a congenital disorder of the bone
marrow characterized by normochromic macrocytic anemia and asso-
ciated with physical malformations and increased risk of malignancies
(Lipton & Ellis, 2009; Vlachos et al., 2008). The penetrance is incom-
plete andawide rangeof clinicalmanifestationsmayoccur evenamong
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affectedmembersof the same family. First-line therapy is steroid treat-
ment; options in steroid-resistant patients are chronic transfusions
or hematopoietic stem cell transplantation. DBA is usually caused by
heterozygous mutations in ribosomal protein (RP) genes that lead to
haploinsufficiency. To date, mutations in 19 RP genes (RPS19, RPS24,
RPS17, RPL35A, RPL5, RPL11, RPS7, RPS10, RPS26, RPL26, RPL15,
RPL31, RPS29, RPS28, RPL27, RPS27, RPS15A, RPL35, RPL18) havebeen
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identified in DBA patients (Cmejla, Cmejlova, Handrkova, Petrak, &
Pospisilova, 2007; Doherty et al., 2010; Draptchinskaia et al., 1999;
Farrar et al., 2008, 2014; Gazda et al., 2006, 2008, 2012; Gripp et al.,
2014; Ikeda et al., 2017; Landowski et al., 2013; Mirabello et al., 2014,
2017; Wang et al., 2015). Rare mutations in GATA1, that abrogate the
production of the full-length protein (Parrella et al., 2014; Sankaran
et al., 2012), and in TSR2, encoding a RPS26 interactor (Gripp et al.,
2014), have also been described.
In DBA, the deficiency of a RP leads to the reduction in the num-
ber of ribosomes and this is particularly harmful for the red cell
progenitors. Ribosome biogenesis is a complex process that requires
the involvement of hundreds of different structural and accessory
molecules. Mature 18S ribosomal RNA (rRNA), which forms the 40S
subunit, together with mature 28S and 5.8S rRNAs, which are com-
ponents of the 60S subunit, are all produced by sequential nucleolytic
cleavages of a large polycistronic 45S precursor. Mutations in RPs of
the small (RPS) or large (RPL) ribosomal subunit affect various steps
of pre-rRNA maturation, resulting in the impairment of ribosome bio-
genesis and function. Since the alterations of pre-rRNA processing
cause the accumulation of specific rRNA precursors depending on the
mutated RP gene (Boria et al., 2010; Farrar et al., 2014; Flygare et al.,
2007), pre-rRNAanalysis has beenproposed as a potential aid formak-
ing a DBA diagnosis (Farrar et al., 2014; Quarello et al., 2016). RPS19
haploinsufficiency affects thematuration of 40S ribosomal subunits by
specifically affecting the conversion of 21S pre-rRNA into 18SE pre-
rRNA (Choesmel et al., 2007; Flygare et al., 2007), thus leading to accu-
mulation of 21S pre-rRNA and increase of 21S/18SE ratio.
While many of the mutations found in RP genes are nonsense,
frameshift, and splice site mutations that can be easily interpreted as
pathogenic based on their predicted effects on the expression of a pro-
tein, the pathogenicity of missense variants remains often controver-
sial. Over 25% of all DBA patients’ mutations are found in RPS19 and
more than 40 different missense mutations and small in-frame indels
have been described in this gene (Boria et al., 2010; Konno et al., 2010;
Ozono et al., 2016; Smetanina et al., 2015; Wang et al., 2015). Their
pathogenic significance is often difficult to evaluate and may present
an obstacle to genetic testing of the proband as well as of family mem-
bers who are silent carriers of the disease. This is particularly rele-
vant when trying to identify a suitable donor for hematopoietic stem
cell transplantation. To be able to counsel patients in these families,
it is necessary to fully understand the role played by these variants of
unknown significance (VUS) on protein expression and function.
In silico tools can aid in the interpretation of VUS and rely on the
following criteria: (i) absence or very low frequency of the variant in
the general population, (ii) change of an evolutionary conserved codon,
(iii) non-conservative amino acid substitution, (iv) cosegregation of the
variant with the disease phenotype in the family under study (Richards
et al., 2015). However, it is not recommended to use these predictions
as the sole source of evidence to reach a diagnostic conclusion, and
functional studies should support the in silico results. A VUS in RPS19
can be classified as benign when the analysis of rRNA maturation in
patient cells points to defects in a different gene. On the contrary, the
observationof pre-rRNAprocessing alterations consistentwithRPS19
loss of function, is not sufficient to interpret the VUS as pathogenic,
since the patient could simultaneously carry a disease-causing muta-
tion, responsible for the defective rRNA processing, in another RP
gene.
We recently characterized the phenotype of lymphoblastoid cell
lines (LCLs) established fromDBApatientswith loss-of-functionmuta-
tions in RPS19 (Aspesi et al., 2017). Aberrant pre-rRNA processing
and other pathological features were rescued by gene complementa-
tion, using an RPS19 transgene carried by a lentiviral vector (Aspesi
et al., 2017). We reasoned that this complementation assay could be
employed to investigate the effects of a wide range of VUS on RPS19
function (Figure 1). Here, we reviewed the literature regarding RPS19
mutations and selected a total of 12 RPS19 variants for functional
analysis.
2 MATERIALS AND METHODS
2.1 Cells
LCLs were established as described previously from two DBA patients
(P1 and P2) and one healthy subject (C), after approval of the local
ethics committee (Aspesi et al., 2017). Both patients had a heterozy-
gous loss-of-functionmutation inRPS19 and their genotypeswere: P1:
c.283_284delG, p.Gly95Alafs*16; P2: c.36_37insAG, p.Glu13Argfs*17
(RefSeq NG_007080.3, NM_001022.3, NP_001013.1). Cells were
maintained in RPMI 1640 medium supplemented with 10% fetal
bovine serum and antibiotics (100U/ml penicillin and 100 𝜇g/ml strep-
tomycin) and were incubated at 37◦C in a humidified atmosphere with
5%CO2.
2.2 Selection of variants for the complementation
assay
From the list of 165 RPS19 mutations described in the literature,
we excluded protein-truncating variants, that is, variants predicted to
lead to nonsense-mediated decay (NMD) and expected to have severe
effects on gene function, as well as variants that disrupt a canonical
splice site. For the present analysis, we considered only VUS: missense
variants, small in-frame indels, and truncating variants located in the
last or penultimate exon. Stop codons located in the penultimate exon
less than 50–55 bases from the final intron are not supposed to cause
NMD (Le Hir, Izaurralde, Maquat, &Moore, 2000), thus the three non-
sense variants in our list (c.376C>T p.Gln126*, c.382C>T p.Gln128*,
c.406G>T p.Gly136*) could theoretically produce truncated proteins.
We chose to select for the complementation assay only the variant
located closest to the 3′ end of the transcript, c.406G>T p.Gly136*.
The novel variant c.338_340delTGG p.Val113del was submitted to
the DBA database LOVD v.2.0 Build 36 (Boria et al., 2008, 2010).
To predict the functional consequences of variants, we used the
following in silico prediction tools: SIFT v.1.03, Polyphen-2 (Polymor-
phismPhenotyping v2), Provean v1.1.3, Condel 2.0,MutationAssessor
release 3, and MutationTaster 2. Mutation Assessor evaluates the
probability that a mutation affects protein function, therefore the
output “low” indicates a neutral variant. For Condel, the score ranges
from 0 (neutral) to 1 (damaging); all variants we studied had an output
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F IGURE 1 Scheme of the complementation assay. Cells from DBA patients have a loss-of-function mutation in RPS19 that cause the accumula-
tion of 21S rRNA. Expression of either wild-type RPS19 or RPS19with a benign sequence variant allows the rescue of the rRNA processing defect.
On the contrary, expression of a RPS19 transgene carrying a deleterious mutation does not recover the pathological phenotype
between 0.5 and 0.9 and we considered them “probably damaging.”
To address the potential effects on gene splicing, we used GeneSplicer,
Human Splicing Finder version 3.1, MaxEntScan, NetGene2 version
2.42, NNSplice version 0.9, and FSPLICE. The presence and frequency
of VUS selected for the complementation assay were evaluated in
population databases: 1000Genomes, GenomeAggregationDatabase
(GnomAD), Exome Variant Server (EVS), and Exome Aggregation
Consortium (ExAC).
2.3 Websites
DBA database, https://www.dbagenes.unito.it/home.php
SIFT, https://sift.jcvi.org
Polyphen-2, https://genetics.bwh.harvard.edu/pph2
Provean, https://provean.jcvi.org/index.php
Condel, https://bbglab.irbbarcelona.org/fannsdb/
Mutation Assessor, https://mutationassessor.org
MutationTaster, https://www.mutationtaster.org
GeneSplicer, https://www.cbcb.umd.edu/software/GeneSplicer/gene_
spl.shtml
Human Splicing Finder, https://www.umd.be/HSF
MaxEntScan, https://genes.mit.edu/burgelab/maxent/Xmaxentscan_
scoreseq.html
NetGene2, https://www.cbs.dtu.dk/services/NetGene2
NNSplice. https://www.fruitfly.org/seq_tools/splice.html
FSPLICE, https://www.softberry.com/berry.phtml?topic=fsplice&gro
up=programs&subgroup=gfind
1000Genomes, https://www.internationalgenome.org/
GnomAD, https://gnomad.broadinstitute.org/
EVS, https://evs.gs.washington.edu/EVS/
ExAC, https://exac.broadinstitute.org/
2.4 Complementation assay
Site-directed mutagenesis on RPS19 cDNA was carried out to intro-
duce the selected variants using the QuikChange Site directed Muta-
genesis kit (Agilent Technologies, Santa Clara, CA, USA). Primers are
available upon request. The presence of each mutation was confirmed
by Sanger sequencing. Lentiviral vectors were produced after tran-
sient transfection of 293T cells with the third generation packaging
plasmids (pMDLg/pRRE, pRSV-REV, and pMD2-VSVG) and with the
transfer construct for each RPS19 transgene (Aspesi et al., 2014; Fol-
lenzi, Ailles, Bakovic, Geuna, & Naldini, 2000). One control (C) and two
RPS19-haploinsufficient LCLs (P1 and P2) were transduced with 10
multiplicity of infection to express the mutant RPs. Integration and
expression of at least one copy of the cassette carrying both RPS19
and green fluorescence protein (GFP) sequences resulted in the emis-
sion of green fluorescence. GFP+ cells were sorted, recultured for 2–
3 weeks and analyzed. Total RNA was isolated using TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA), followed by on-column DNase treat-
ment and purification with miRNeasy Mini Kit (Qiagen, Milano, Italy).
For Northern blot analysis, 5 𝜇g of total RNAwas fractionated on 1.5%
formaldehyde agarose gels, transferred to a positively charged nylon
membrane (Roche, Monza, Italy) and immobilized on the membrane
by UV-crosslinking performed with 120 milliJoules/cm2. The oligonu-
cleotide probe (5′-CCTCGCCCTCCGGGCTCCGTTAATGATC-3′) was
labeledwith [𝛾-32P]ATP using T4 polynucleotide kinase and hybridized
overnight with the membrane at 37◦C in ULTRAHyb-Oligonucleotide
hybridization buffer (Ambion, Thermo Fisher Scientific, Waltham, MA,
USA). The membrane was washed at 37◦C with 6XSSC and subjected
to phosphorimaging analysis (Flygare et al., 2007). The overexpression
of RPS19 did not cause adverse effects on pre-rRNAprocessing in con-
trol cells (Aspesi et al., 2017), nor did the expression of RPS19mutants
(Figure 2A).
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F IGURE 2 Complementation assay on VUS reported in DBA patients. A: Representative Northern blot experiments. Patient cells have an
increased 21S/18SE rRNA ratio, that is corrected by the expression of a wild-type RPS19 transgene but not by the expression of RPS19 carry-
ing a pathogenic mutation. Upper panels showNorthern blotting, lower panels show corresponding RNA gels stained by a fluorescent nucleic acid
dye. C: control, P1: patient 1, P2: patient 2. B: Densitometry quantification of 21S/18SE ratio calculated on repeated Northern blot experiments.
Asterisks represent statistically significant differences (P< 0.05) between samples withwild-type andmutant exogenous RPS19. Error bars repre-
sent standard error of themean
2.5 Quantitative RT-PCR
RNA isolated from cells with wild-type or mutant exogenous RPS19
was reverse transcribed using the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA). Real-time
PCR amplification of cDNA was performed in triplicate using Power
SYBR R© Green PCR Master Mix (Applied Biosystems) and specific
primers for the target genes RPS19 and CDKN1A (p21). ACTB (𝛽-actin)
was used as reference gene.
2.6 Statistical analysis
Northern blot bands were quantified using the ImageJ software.
Results from P1 and P2 patient cells were considered as biological
replicates. Differences in mean values between samples with either
wild-type or mutant exogenous RPS19 were analyzed with theMann–
Whitney test for two-taileddata. Statistical significancewasdefinedby
a P value≤0.05.
3 RESULTS
3.1 Selection of variants and in silico analyses
TheDBAdatabase (Boria et al., 2008, 2010) included 129RPS19muta-
tions in 219 patients at its last update in 2010. We reviewed the
literature to collect additional RPS19 mutations identified more
recently and now have a total of 165 different RPS19 mutations
reported in 313 DBA patients (Arbiv et al., 2017; Chae et al., 2010,
2014; Da Costa et al., 2013; Delaporta et al., 2014; Errichiello et al.,
2017; Farrar et al., 2011; Gerrard et al., 2013; Ichimura et al., 2017;
Konno et al., 2010; Kuramitsu et al., 2012; Landowski et al., 2013;
Ozono et al., 2016; Pospisilova et al., 2012; Quarello et al., 2012;
Smetanina et al., 2015; Solomon et al., 2014; Tsangaris et al., 2011;
van Dooijeweert et al., 2017; Wang et al., 2015; Zhang et al., 2016).
For our study, we selected only those variants for which there was
no strong evidence of pathogenicity according to the genetic crite-
ria outlined in Materials and Methods, and obtained 47 VUS reported
in 122 patients (39% of RPS19-mutated patients, approximately 10%
of all DBA patients). We also included a new previously unpublished
variant we identified in a DBA patient by next-generation sequenc-
ing, c.338_340delTGG p.Val113del (Supp. Table S1). Thirteen of the
VUS have already been found to be pathogenic by published functional
studies (Angelini et al., 2007; Badhai et al., 2009; Chatr-Aryamontri
et al., 2004; Chae et al., 2014; Choesmel et al., 2007; Cmejlova et al.,
2006; DaCosta et al., 2003; Gazda et al., 2004; Hamaguchi et al., 2002;
Idol et al., 2007;) (Supp. Table S1) and sowere not tested in our study.
The VUS were analyzed by multiple in silico tools to predict the
impact of sequence variants on protein function. Five missense
variants that were analyzed were considered tolerated/benign by at
least one of the six in silico tools indicating some degree of ambiguity
as to whether or not they could be the pathogenic lesion in these
patients. These were all selected for functional analysis using the
complementation assay outlined here (Table 1). We also chose to
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TABLE 1 VUS in RPS19 identified in DBA patients selected for complementation assay
DNA
change
Protein
change
Mutation
taster
Mutation
assessor Polyphen-2 Provean SIFT Condel
Affected
patients
c.1A>G p.Met1? Disease
causing
na Probably
damaging
Neutral Damaging Probably
damaging
5
c.62T>C p.Phe21Ser Disease
causing
Medium Probably
damaging
Deleterious Tolerated Probably
damaging
1
c.187_189
insCAC
p.His63dup Disease
causing
na na Deleterious na na 1
c.281G>T p.Arg94Leu Polymorphism Medium Benign Deleterious Tolerated Probably
damaging
1
c.305G>C p.Arg102Pro Disease
causing
Medium Benign Deleterious Damaging Probably
damaging
1
c.353A>G p.Asp118Gly Disease
causing
Low Benign Deleterious Tolerated Probably
damaging
1
c.406G>T p.Gly136* Disease
causing
na na na na na 1
c.338_340
delTGG
p.Val113del Disease
causing
na na Deleterious na na 1
na, not available. RefSeq: NM_001022.3, NP_001013.1.
Numeric output data are shown in Supp. Table S1.Websites and software versions are reported in theMaterials andMethods section.
study a nonsense VUS late in the coding sequence predicted to escape
nonsense-mediated mRNA decay (Le Hir et al., 2000) as well as two
small in-frame indels, whose impact could not be determined by most
prediction algorithms (Table 1). As negative controls for the effect of
known loss-of-function mutations, we chose a nonsense mutation,
c.166C>T p.Arg56*, previously reported in four DBA patients (Boria
et al., 2010; Proust et al., 2003; Willig et al., 1999) and the missense
c.178A>C p.Thr60Pro, reported in one patient and predicted as dam-
aging by every in silico tool we used. None of the variants chosen for
functional analysis here were reported in 1000 Genomes, GnomAD,
EVS, and ExAC.
Finally, we assessed whether the VUS we selected caused the cre-
ation or loss of splice sites by in silico tools. These prediction tools have
low specificity (∼60%–80%), but quite high sensitivity (∼90%–100%)
in predicting splice site abnormalities, and therefore have a low false
negative rate (Houdayer et al., 2012; Richards et al., 2015). None
of the VUS included in this study were predicted to affect splicing,
but the variant c.353A>G that, according to Human Splicing Finder,
MaxEntScan, and FSPLICE, could activate a cryptic donor splice site
(data not shown).
3.2 Analysis of VUS by complementation assay
Our previous findings showed that transfection of RPS19-
haploinsufficient LCLs with a vector expressing RPS19 cDNA
corrected the abnormal accumulation of 21S pre-rRNA, a well-
established defect in ribosome biogenesis caused by the loss of RPS19
function. Ribosome biogenesis defects such as these have been a
hallmark of DBA pathogenesis in patients harboring mutations in
RP genes. To assess the function of individual variants selected, we
asked whether the variants could rescue the pre-rRNA processing
defect in the complementation assay outlined in Figure 1. Cells
expressing themutant transgenes showed an increased level of RPS19
transcript compared to parental cells, as measured by quantitative
RT-PCR (Supp. Figure S1A); Sanger sequencing performed on cDNA
demonstrated the presence of the mutated transcripts (Supp. Figure
S1B). Processing of pre-rRNAs was evaluated by Northern blotting
and results obtained by expressing wild-type or mutant transgenes
were compared. Representative experiments are shown in Figure 2A.
Patient cells with no exogenous RPS19 (i.e., parental cells) or with the
negative control p.Arg56* RPS19 had a mean 21S/18SE rRNA ratio
of 2.97 ± 0.21 (standard deviation, SD) and 2.69 ± 0.31, respectively,
whereas patient cells expressing thewild-type transgene had a ratio of
1.20 ± 0.11, similar to the value of cells from healthy donors, that was
1.13 ± 0.13 (Figure 2A and B). Densitometry of Northern blots (Fig-
ure 2B) showed statistically significant differences (P < 0.05) between
samples with wild-type and mutant exogenous RPS19, demonstrating
that all tested VUS were unable to recover the pathogenic pheno-
type of RPS19-deficient cells. The only exception was c.281G>T
p.Arg94Leu (mean 21S/18SE ratio 1.43 ± 0.12), which showed no
statistical difference fromwild-type RPS19.
According to our data, we propose an arbitrary 21S/18SE cut-off
value ≥2 to define pathogenicity and ≤1.5 to indicate normal protein
function. None of the mutants we analyzed showed a 21S/18SE ratio
between these two values.
3.3 Analysis of variants found in population
databases
Population databases such as 1000 Genomes, GnomAD, EVS, and
ExACwere searched for polymorphisms in RPS19 that cause missense
substitutions. Overall amino acid changes in RPS19 were extremely
rare in population databases. No missense variant was present in
1000 Genomes, which includes data from more than 5,000 healthy
subjects. The two most common variants in GnomAD, EVS, and ExAC,
were c.68A>G p.Lys23Arg and c.164C>T p.Thr55Met (Table 2). These
variants are presumed to be benign since it seems unlikely that individ-
uals included in these databases would have a rare disease like DBA.
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TABLE 2 VUS in RPS19 selected from population databases
Population database (MAF)
DNA
change
Protein
change
1000
genomes GnomAD ExAC EVS
Mutation
taster
Mutation
assessor Polyphen-2 Provean SIFT Condel
c.68A>G p.Lys23Arg Not
reported
0.0001292 0.0001895 0.0002071 Disease
causing
score 26
Medium
score 2.29
Benign
score 0.097
Deleterious
score
−2.601
Damaging
score 0.03
Probably
damaging
score
0.617
c.164C>T p.Thr55Met Not
reported
0.0002261 0.0002734 0.0002478 Disease
causing
score 81
Medium
score 2.08
Possibly
damaging
score 0.926
Neutral
score
−1.889
Tolerated
score 0.06
Probably
damaging
score
0.647
MAF, minor allele frequency. RefSeq: NM_001022.3, NP_001013.1.
Mutation Taster: the score for amino acid substitutions reflects the physicochemical difference between the original and the mutated amino acid but does
not influence the prediction. Mutation Assessor: the Functional Impact score is reported. PROVEAN: a score equal to or below the predefined threshold
(−2.5) predicts a deleterious effect for the protein variant; a score above the threshold indicates that the variant is predicted to have a neutral effect. SIFT:
the score predicts whether an amino acid substitution affects protein function, and ranges from 0.0 (deleterious) to 1.0 (tolerated).
Websites and software versions are shown in theMaterials andMethods section.
F IGURE 3 Complementation assay on VUS found in population databases. A: Representative Northern blot experiment. Upper panel shows
Northern blot, lower panel shows the corresponding RNA gel stained by a fluorescent nucleic acid dye. C: control, P1: patient 1, P2: patient 2.
B: Densitometry quantification of 21S/18SE ratio shows that neither variant could rescue the defective rRNA processing in patients cells. Aster-
isks represent statistically significant differences (P < 0.05) between samples with wild-type and mutant exogenous RPS19. Error bars represent
standard error of themean
Interestingly, variants c.68A>Gp.Lys23Arg and c.164C>Tp.Thr55Met
were predicted to be benign only by one out of six and two out of
six bioinformatic tools, respectively. Northern blot analysis showed
that these variants failed to rescue the pre-rRNA processing defects
in patient lymphoblasts (Figure 3A). The mean 21S/18SE ratios for
variants p.Lys23Arg and p.Thr55Metwere 2.09±0.13 and 2.01±0.07,
respectively, andwere significantly different fromdata obtainedby the
wild-type transgene, suggesting that these amino acid substitutions
impair, at least partially, protein function (Figure 3A and B).
3.4 Evaluation of p21 transcript level
RPS19 deficiency induces stabilization of p53 and increased level of its
target p21; such alterations are recovered by expression of the RPS19
transgene (Aspesi et al., 2017). We performed quantitative RT-PCR
to measure the level of p21 transcript in patient cells expressing the
mutant transgenes. The results validated the data obtained by North-
ern blot analysis, since the expression of RPS19mutants could not nor-
malize the level of p21, but the expression ofmutant p.Arg94Leu led to
a clear, though not significant, decrease of p21 (Figure 4). Interestingly,
the high p21 levels measured for the VUS p.Lys23Arg and p.Thr55Met
corroborate their interpretation as deleterious variants (Figure 4).
4 DISCUSSION
Ourworkwas aimed at creating a complementation assay to assess the
function of RPS19 VUS and clarify their involvement in the pathogen-
esis of DBA. Novel sequence variants in genes known to be involved
in DBA have been increasingly detected, but our understanding of the
clinical significance of these novel variants is often limited. Many of
the most challenging variants change only one amino acid, making it
difficult to discern benign variants from pathogenic mutations that
disrupt protein function. In silico prediction tools can be of aid in
the interpretation of sequence variants but their output should be
validated by functional studies.
1108 ASPESI ET AL.
F IGURE 4 Level of p21 transcript in patient cells expressingwild-type ormutant RPS19. The increased level of p21 typical of DBApatient cells is
corrected by the expression of a wild-type RPS19 transgene but not by the expression of RPS19 carrying a pathogenic mutation. Results obtained
by quantitative RT-PCR performed on P1 and P2 patient cells were considered biological replicates. Asterisks represent statistically significant
differences between samples with wild-type andmutant exogenous RPS19: *P< 0.05; **P< 0.01. Error bars represent standard error of themean
It is widely accepted that the underlying pathophysiology in
the majority of DBA patients is haploinsufficiency for a RPs and
an ensuing disruption of ribosome biogenesis. RPS19 is the most
frequently mutated gene in DBA and structure/function relation-
ships of known pathogenic mutations have been characterized pre-
viously. The crystal structure of RPS19 from the archeon Pyroccocus
abyssi was used to group RPS19 missense mutations in two classes:
class I included residues essential for the folding and stability of
the protein, whereas class II included mutations that affected sur-
face residues and presumably impaired the capacity of RPS19 to
engage intermolecular interactions (Gregory et al., 2007). In another
study, eleven missense mutations and one trinucleotide insertion
were expressed in human HEK293 cells (Angelini et al., 2007). Some
mutants, corresponding to class I mutants (p.Val15Phe, p.Leu18Pro,
p.Ala57Pro, p.Ala61Glu, p.Gly127Glu, and p.Leu18_Ala19insGlu) were
expressed at a barely detectable level, whereas the others (all
class II mutants: p.Pro47Leu, p.Trp52Arg, p.Arg56Gln, p.Arg62Gln,
p.Arg62Trp, p.Arg101His), although more stable, were not assembled
intomature ribosomes.
Additional studies have shown that missense mutations can influ-
ence the localization of RPS19 and disrupt function bymislocalization.
For example, mutant proteins such as p.Val15Phe, p.Gly127Gln, and
p.Leu131Pro could not reach the nucleolus and their expression was
dramatically decreased compared with the wild-type protein (Cretien
et al., 2008; Da Costa et al., 2003).
Because of the limitations associated with assessing a protein's
function based on sequence analysis alone, there is a significant need
to be able to functionally annotate novel sequence variants for their
potential involvement in DBA pathogenesis.We have developed a new
complementation assay to assess a variant's function based on its abil-
ity to rescue a pre-rRNA processing defect in lymphoblasts derived
from patients haploinsufficient for RPS19. This assay is not restricted
to RPS19 and could potentially be developed for other known DBA
genes.
We functionally tested 12 variants: nine were already described
in the literature as mutations responsible for DBA, one was a new
variant we identified in a DBA patient and two variants were selected
from population databases. Among the variants we analyzed, only the
missense c.281G>T p.Arg94Leu successfully rescued the rRNA pro-
cessing defect in patient cells. This variant was reported as pathogenic
after the identification in a female DBA patient whose parents were
not tested (Boria et al., 2010). Our results suggest that this variant
may actually be benign and further studies should be carried out in
this patient to establish the causative gene. The remaining variants
c.1A>G p.Met1?, c.62T>C p.Phe21Ser, c.187_189insCAC p.His63dup,
c.305G>C p.Arg102Pro, c.353A>G p.Asp118Gly and c.406G>T
p.Gly136* were not able to complement RPS19 deficiency. Among the
variant failing to complement was the new variant c.338_340delTGG
p.Val113del, whose impact was difficult to predict even by bioinfor-
matic algorithms.
The most surprising result from our analysis was that two rare
variants selected from population databases, c.68A>G p.Lys23Arg,
and c.164C>T p.Thr55Met failed to complement the pre-rRNA pro-
cessing defect in patient lymphoblasts. The latter variant was previ-
ously observed in a DBA patient who also carried a second variant,
p.Val15Phe, on the same allele. In this case, p.Val15Phewas considered
pathogenic, whereas p.Thr55Met was interpreted as benign because
only protein localizationwasbeing studied (Boria et al., 2008;DaCosta
et al., 2003).
There is growing evidence that RP mutations can be found in
patients with very mild or absent hematologic manifestations, as
previously described, for instance, in a family with no sign of DBA
where a truncating germline mutation in RPS20 cosegregated with
colon cancer (Nieminen et al., 2014). This is also supported by the
recent report of two unrelated patients with congenital heart dis-
ease and mutations in RPS24 who were not anemic (Vlachos et al.,
2018). Our observation that VUS reported in population databases
could be involved in DBA pathogenesis highlights the need to
deepen our knowledge about the possible presence in the general
population of silent carriers of RP mutations and atypical cases
of DBA.
Our results also emphasize the limited reliability of in silico tools for
pathogenicity prediction. According to the data obtained by our com-
plementation assay, Mutation Taster was the only tool with sensitivity
and specificity equal to 1,whereas the other tools resulted in false neg-
ative and/or false positive predictions.
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Several VUS have been reported also in other RP genes mutated
in DBA patients (Arbiv et al., 2017; Doherty et al., 2010; Gerrard
et al., 2013; Konno et al., 2010; Pospisilova et al., 2012; Smetanina
et al., 2015; Tsangaris et al., 2011; van Dooijeweert et al., 2017). In the
future, appropriate complementation assays could be implemented to
extend the study of pathogenicity to other DBA genes, similarly to the
approachwe developed for RPS19.
In conclusion, we provided a strategy to distinguish disease-causing
mutations in RPS19 from benign polymorphisms and clarify their clini-
cal significance. This information should assist clinicians in the counsel-
ing andmanagement of DBA patients and their families.
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